The utility of Hedgehog signaling pathway inhibition for cancer

Oncologist

Volumn 17, Issue 8, 2012, Pages 1090-1099

  Sahebjam, Solmaz ^a   Siu, Lillian L ^a   Razak, Albiruni A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Arsenic; Cancer; Cancer stem cells; Hedgehog; PTCH; SMO

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BEVACIZUMAB; BMS 833923; BORTEZOMIB; BOSUTINIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DASATINIB; DEXAMETHASONE; ERISMODEGIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HEDGEHOG INHIBITOR; IRINOTECAN; LEQ 506; MITOGEN ACTIVATED PROTEIN KINASE P38; OXALIPLATIN; PACLITAXEL; PF 04449913; PROTEIN INHIBITOR; PROTEIN PATCHED 1; SARIDEGIB; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; TAK 441; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR GLI3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISMODEGIB; XL 139;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL CELL CARCINOMA; BILIRUBIN BLOOD LEVEL; CANCER STEM CELL; CHONDROSARCOMA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIARRHEA; DRUG DOSE ESCALATION; DYSGEUSIA; FATIGUE; GENE MUTATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LEUKEMIA; LUNG SMALL CELL CANCER; MEDULLOBLASTOMA; MUSCLE CRAMP; MUSCLE SPASM; MYALGIA; MYELOMA; NAUSEA; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATITIS; PARANOIA; PRESYNCOPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PYELONEPHRITIS; RECOMMENDED DRUG DOSE; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84865270456     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0450     Document Type: Article

References (115)

1. Varjosalo M, Bjorklund M, Cheng F et al. Application of active and kinase-deficient kinome collection for identification of kinases regulating Hedgehog signaling. Cell 2008;133:537-548.
2. Varjosalo M, Taipale J. Hedgehog: Functions and mechanisms. Genes Dev 2008;22:2454-2472.
3. Wicking C, Smyth I, Bale A. The Hedgehog signalling pathway in tumorigenesis and development. Oncogene 1999;18:7844-7851.
4. Hahn H, Wicking C, Zaphiropoulous PG et al. Mutations of the human homolog of drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996;85: 841-851.
5. Wang Q, Huang C, Zeng F et al. Activation of the Hh pathway in periosteum-derived mesenchymal stem cells induces bone formation in vivo: Implication for postnatal bone repair. Am J Pathol 2010;177:3100-3111.
6. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004;432:324-331.
7. Levi B, James AW, Nelson ER et al. Human adipose-derived stromal cells stimulate autogenous skeletal repair via paracrine Hedgehog signaling with calvarial osteoblasts. STEM CELLS Dev 2011;20:243-257.
8. Watkins DN, Berman DM, Burkholder SG et al. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003;422:313-317.
9. Low JA, de Sauvage FJ. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol 2011;28: 5321-5326.
10. Merchant AA, Matsui W. Targeting Hedgehog-A cancer stem cell pathway. Clin Cancer Res 2010;16: 3130-3140.
11. Mazumdar T, Devecchio J, Agyeman A et al. Blocking Hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells. Cancer Res 2011;71:5904-5914.
12. Goetz SC, Anderson KV. The primary cilium: A signalling centre during vertebrate development. Nat Rev Genet 2010;11:331-344.
13. Ruiz i Altaba A, Sanchez P, Dahmane N. GLI and Hedgehog in cancer: Tumours, embryos and stem cells. Nat Rev Cancer 2002;2:361-372.
14. Ruiz i Altaba A, Mas C, Stecca B. The GLI code: An information nexus regulating cell fate, stemness and cancer. Trends Cell Biol 2007;17:438-447.
15. Stecca B, Ruiz IAA. Context-dependent regulation of the GLI code in cancer by Hedgehog and non-Hedgehog signals. J Mol Cell Biol 2010;2:84-95.
16. Jiang J. Regulation of Hh/GLI signaling by dual ubiquitin pathways. Cell Cycle 2006;5:2457-2463.
17. Pearse RV 2nd, Collier LS, Scott MP et al. Vertebrate homologs of drosophila suppressor of fused interact with the GLI family of transcriptional regulators. Dev Biol 1999;212:323-336.
18. Wong SY, Reiter JF. The primary cilium at the crossroads of mammalian Hedgehog signaling. Curr Top Dev Biol 2008;85:225-260.
19. Barnfield PC, Zhang X, Thanabalasingham V et al. Negative regulation of GLI1 and GLI2 activator function by suppressor of fused through multiple mechanisms. Differentiation 2005;73:397-405.
20. Svard J, Heby-Henricson K, Persson-Lek M et al. Genetic elimination of suppressor of fused reveals an essential repressor function in the mammalian hedgehog signaling pathway. Dev Cell 2006;10:187-197.
21. Kogerman P, Grimm T, Kogerman L et al. Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of Gli-1. Nat Cell Biol 1999;1:312-319.
22. Cheung HO, Zhang X, Ribeiro A, et al. The kinesin protein Kif7 is a critical regulator of Gli transcription factors in mammalian Hedgehog signaling. Sci Signal 2009;2:ra29.
23. Liem KF, Jr. He M, Ocbina PJ et al. Mouse Kif7/ Costal2 is a cilia-associated protein that regulates sonic hedgehog signaling. Proc Natl Acad Sci U S A 2009;106:13377-13382.
24. Ailles L, Siu LL. Targeting the Hedgehog pathway in cancer: Can the spines be smoothened? Clin Cancer Res 2011;17:2071-2073.
25. Gailani MR, Stahle-Backdahl M, Leffell DJ et al. The role of the human Homologue of drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996;14: 78-81.
26. Dahmane N, Lee J, Robins P et al. Activation of the transcription factor GLI1 and the sonic Hedgehog signalling pathway in skin tumours. Nature 1997;389:876-881.
27. Aszterbaum M, Rothman A, Johnson RL et al. Identification of mutations in the human patched gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol 1998;110: 885-888.
28. Lam CW, Xie J, To KF et al. A frequent activated Smoothened mutation in sporadic basal cell carcinomas. Oncogene 1999;18:833-836.
29. Lee Y, Miller HL, Jensen P et al. A molecular fingerprint for medulloblastoma. Cancer Res 2003;63: 5428-5437.
30. Raffel C, Jenkins RB, Frederick L et al. Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997;57:842-845.
31. Wolter M, Reifenberger J, Sommer C et al. Mutations in the human homologue of the drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1997;57: 2581-2585.
32. Goodrich LV, Milenkovic L, HigginsKMet al. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997;277:1109-1113.
33. Oro AE, Higgins KM, Hu Z et al. Basal cell carcinomas in mice overexpressing sonic Hedgehog. Science 1997;276:817-821.
34. Bale AE, Yu KP. The Hedgehog pathway and basal cell carcinomas. Hum Mol Genet 2001;10:757-762.
35. Reifenberger J, Wolter M, Weber RG et al. Missense mutations in smoh in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998;58:1798-1803.
36. Xie J, Murone M, Luoh SM et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature 1998;391:90-92.
37. Slade I, Murray A, Hanks S et al. Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma. Fam Cancer 2011;10:337-342.
38. Taylor MD, Liu L, Raffel C et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002;31:306-310.
39. Jones S, Zhang X, ParsonsDWet al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-1806.
40. Caro I, Low JA. The role of the Hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment. Clin Cancer Res 2010;16:3335-3339.
41. Park KS, Martelotto LG, Peifer M et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med 2011;17:1504-1508.
42. Gialmanidis IP, Bravou V, Amanetopoulou SG et al. Overexpression of Hedgehog pathway molecules and FOXM1 in non-small cell lung carcinomas. Lung Cancer 2009;66:64-74.
43. Kubo M, Nakamura M, Tasaki A et al. Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res 2004;64:6071-6074.
44. Katano M. Hedgehog signaling pathway as a therapeutic target in breast cancer. Cancer Lett 2005;227: 99-104.
45. Cui W, Wang LH, Wen YY et al. Expression and regulation mechanisms of sonic Hedgehog in breast cancer. Cancer Sci 2010;101:927-933.
46. Bhattacharya R, Kwon J, Ali B et al. Role of Hedgehog signaling in ovarian cancer. Clin Cancer Res 2008;14:7659-7666.
47. Liao X, Siu MK, Au CW et al. Aberrant activation of Hedgehog signaling pathway in ovarian cancers: Effect on prognosis, cell invasion and differentiation. Carcinogenesis 2009;30:131-140.
48. Ray A, Meng E, Reed E et al. Hedgehog signaling pathway regulates the growth of ovarian cancer spheroid forming cells. Int J Oncol 2011;39:797-804.
49. Meyers-Needham M, Lewis JA, Gencer S et al. Off-target function of the sonic-Hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxidedependent neutral sphingomyelinase 2/ceramide induction. Mol Cancer Ther 2012;11:1092-1102.
50. Braun S, Oppermann H, Mueller A et al. Hedgehog signaling in glioblastoma multiforme. Cancer Biol Ther 2012;13:487-495.
51. Lipinski RJ, Hutson PR, Hannam PW et al. Doseand route-dependent teratogenicity, toxicity, and pharmacokinetic profiles of the Hedgehog signaling antagonist cyclopamine in the mouse. Toxic Sci 2008;104: 189-197.
52. Ng JM, Curran T. The Hedgehog's tale: Developing strategies for targeting cancer. Nat Rev Cancer 2011;11:493-501.
53. Yauch RL, Gould SE, Scales SJ et al. A paracrine requirement for Hedgehog signalling in cancer. Nature 2008;455:406-410.
54. Dierks C, Grbic J, Zirlik K et al. Essential role of stromally induced Hedgehog signaling in B-cell malignancies. Nat Med 2007;13:944-951.
55. Clement V, Sanchez P, de Tribolet N et al. Hedgehog-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007;17:165-172.
56. Feldmann G, Dhara S, Fendrich V et al. Blockade of Hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res 2007;67:2187-2196.
57. Liu S, Dontu G, Mantle ID et al. Hedgehog signaling and BMI-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006;66:6063-6071.
58. Zhao C, Chen A, Jamieson CH et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009;458:776-779.
59. Bar EE, Chaudhry A, Lin A et al. Cyclopaminemediated Hedgehog pathway inhibition depletes stemlike cancer cells in glioblastoma. STEMCELLS 2007;25: 2524-2533.
60. Rasheed ZA, Yang J, Wang Q et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010;102:340-351.
61. Pannuti A, Foreman K, Rizzo P et al. Targeting notch to target cancer stem cells. Clin Cancer Res 2010;16:3141-3152.
62. Takahashi-Yanaga F, Kahn M. Targeting wnt signaling: Can we safely eradicate cancer stem cells? Clin Cancer Res 2010;16:3153-3162.
63. Varnat F, Duquet A, MalerbaMet al. Human colon cancer epithelial cells harbour active Hedgehog-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med 2009;1:338-351.
64. Rudin CM, Hann CL, Laterra J et al. Treatment of medulloblastoma with Hedgehog pathway inhibitor GDC-0449. New Engl J Med 2009;361:1173-1178.
65. Von Hoff DD, Lo Russo PM, Rudin CM et al. Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma. New Engl J Med 2009;361:1164-1172.
66. Berlin J. A phase 2, randomized, double-blind, placebo-controlled study of Hedgehog pathway inhibitor (Hpi) GDC-0449 in patients with previously untreated metastatic colorectal cancer (mcrc). ESMO Meeting Abstracts 2010;21:viii10.
67. Fehrenbacher L, Kaye S, Holloway R. A phase 2, randomized, placebo-controlled study of Hedgehog (Hh) pathway inhibitor GDC-0449 as maintenance therapy in patients with ovarian cancer in 2nd or 3rd complete remission (CR). ESMO Meeting Abstracts 2010;21:viii11.
68. Robarge KD, Brunton SA, Castanedo GM et al. GDC-0449: A potent inhibitor of Hedgehog pathway. Bioorg Med Chem Lett 2009;19:5576-5581.
69. Lo Russo PM, Rudin CM, Reddy JC et al. Phase I trial of Hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17:2502-2511.
70. Lorusso PM, Jimeno A, Dy G et al. Pharmacokinetic dose-scheduling study of Hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17:5774-5782.
71. Sekulic A, Migden MR, Oro AE et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. New Engl J Med 2012;366:2171-2179.
72. Tang JY, Mackay-Wiggan JM, Aszterbaum M et al. Inhibiting the Hedgehog pathway in patients with the basal-cell nevus syndrome. New Engl J Med 2012;366: 2180-2188.
73. Siu LL, Papadopoulos K, Alberts SR et al. A firstin-human, phase I study of an oral Hedgehog (Hh) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors ASCO Meeting Abstracts 2010;28:2501.
74. Tremblay MR, Nesler M, Weatherhead R et al. Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy. Expert Opin Ther Pat 2009;19: 1039-1056.
75. Tremblay MR, Lescarbeau A, Grogan MJ et al. Discovery of a potent and orally active Hedgehog pathway antagonist (IPI-926). J Med Chem 2009;52:4400-4418.
76. Olive KP, Jacobetz MA, Davidson CJ et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-1461.
77. Rudin CM, Jimeno A, Miller WH et al. A phase I study of IPI-926, a novel Hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors. ASCO Meeting Abstracts 2011;29:3014.
78. Rodon Ahnert J, Baselga J, Tawbi HA et al. A phase I dose-escalation study of LDE225, a Smoothened (SMO) antagonist, in patients with advanced solid tumors. ASCO Meeting Abstracts 2010;28:2500.
79. Skvara H, Kalthoff F, Meingassner JG et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a Smoothened inhibitor. J Invest Dermatol 2011;131:1735-1744.
80. Kim J, Lee JJ, Gardner D et al. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the GLI2 transcriptional effector. Proc Natl Acad Sci U S A 2010;107:13432-13437.
81. Beauchamp E, Bulut G, Abaan O et al. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem 2009;284:9074-9082.
82. Beauchamp EM, Ringer L, Bulut G et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Inv 2011;121:148-160.
83. Mazumdar T, DeVecchio J, Shi T et al. Hedgehog signaling drives cellular survival in human colon carcinoma cells. Cancer Res 2011;71:1092-1102.
84. Lauth M, Bergstrom A, Shimokawa T et al. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A 2007;104:8455-8460.
85. Xu Y, Chenna V, Hu C et al. A polymeric nanoparticle encapsulated hedgehog pathway inhibitor HPI-1 (nanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 2011;18:1291-1302.
86. Yauch RL, Dijkgraaf GJ, Alicke B et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009;326:572-574.
87. Dijkgraaf GJ, Alicke B, Weinmann L et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res 2011;71:435-444.
88. Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to Smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010;2:51ra70.
89. Mackie EJ, Tatarczuch L, Mirams M. The skeleton: A multi-functional complex organ: The growth plate chondrocyte and endochondral ossification. J Endocrinol 2011;211:109-121.
90. Fuchs S, Dohle E, Kirkpatrick CJ. Sonic Hedgehog-mediated synergistic effects guiding angiogenesis and osteogenesis. Vitam Horm 2012;88:491-506.
91. Ohba S, Kawaguchi H, Kugimiya F et al. Patched1 haploinsufficiency increases adult bone mass and modulates GLI3 repressor activity. Dev Cell 2008;14:689-699.
92. Kimura H, Ng J, Curran T. Transient inhibition of the hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell 2008;13:249-260.
93. Fiaschi M, Rozell B, Bergstrom A et al. Development of mammary tumors by conditional expression of gli1. Cancer Res 2009;69:4810-4817.
94. Toftgard R. Hedgehog signalling in cancer. Cell Mol Life Sci 2000;57:1720-1731.
95. Dahmane N, Sanchez P, Gitton Y et al. The sonic Hedgehog-GLI pathway regulates dorsal brain growth and tumorigenesis. Development 2001;128:5201-5212.
96. Ehtesham M, Sarangi A, Valadez JG et al. Liganddependent activation of the Hedgehog pathway in glioma progenitor cells. Oncogene 2007;26:5752-5761.
97. Irvine DA, Copland M. Targeting hedgehog in hematologic malignancy. Blood 2012;119:2196-2204.
98. Vestergaard J, Pedersen MW, Pedersen N et al. Hedgehog signaling in small-cell lung cancer: Frequent in vivo but a rare event in vitro. Lung Cancer 2006;52: 281-290.
99. Velcheti V, Govindan R. Hedgehog signaling pathway and lung cancer. J Thorac Oncol 2007;2:7-10.
100. Hegde GV, Munger CM, Emanuel K et al. Targeting of sonic Hedgehog-GLI signaling: A potential strategy to improve therapy for mantle cell lymphoma. Mol Cancer Ther 2008;7:1450-1460.
101. Lindemann RK. Stroma-initiated Hedgehog signaling takes center stage in B-cell lymphoma. Cancer Res 2008;68:961-964.
102. Singh RR, Cho-Vega JH, Davuluri Y et al. Sonic hedgehog signaling pathway is activated in alk-positive anaplastic large cell lymphoma. Cancer Res 2009;69: 2550-2558.
103. Singh RR, Kim JE, Davuluri Y et al. Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation. Leukemia 2010;24:1025-1036.
104. Peacock CD, Wang Q, Gesell GS et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A 2007;104: 4048-4053.
105. Byrom J, Mudaliar V, Redman CW et al. Loss of heterozygosity at chromosome 9q22-31 is a frequent and early event in ovarian tumors. Int J Oncol 2004;24: 1271-1277.
106. Tian H, Callahan CA, Kelly J et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A 2009;106:4254-4259.
107. Thayer SP, di Magilano MP, Heiser PW et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003;425:851-856.
108. Karhadkar SS, Bova GS, AbdallahNet al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004;431:707-712.
109. Sanchez P, Hernandez AM, Stecca B et al. Inhibition of prostate cancer proliferation by interference with sonic Hedgehog-GLI1 signaling. Proc Natl Acad Sci U S A 2004;101:12561-12566.
110. Chen M, Tanner M, Levine AC et al. Androgenic regulation of Hedgehog signaling pathway components in prostate cancer cells. Cell Cycle 2009;8:149-157.
111. Berman DM, Karhadkar SS, Maitra A et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003;425: 846-851.
112. Tostar U, Toftgard R, Zaphiropoulos PG et al. Reduction of human embryonal rhabdomyosarcoma tumor growth by inhibition of the Hedgehog signaling pathway. Genes Cancer 2010;1:941-951.
113. Tostar U, Malm CJ, Meis-Kindblom JM et al. Deregulation of the hedgehog signalling pathway: A possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. J Pathol 2006;208:17-25.
114. Zwerner JP, Joo J, Warner KL et al. The EWS/ FLI1 oncogenic transcription factor deregulates GLI1. Oncogene 2008;27:3282-3291.
115. Hirotsu M, Setoguchi T, Sasaki H et al. Smoothened as a new therapeutic target for human osteosarcoma. Mol Cancer 2010;9:5.